Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 7;15(1):211.
doi: 10.3390/pharmaceutics15010211.

The Progress of Chitosan-Based Nanoparticles for Intravesical Bladder Cancer Treatment

Chong Yu  1 , Shuai Wang  1 , Wing-Fu Lai  1   2 , Dahong Zhang  1
Affiliations
Review

The Progress of Chitosan-Based Nanoparticles for Intravesical Bladder Cancer Treatment

Chong Yu et al. Pharmaceutics. .

Abstract

Bladder cancer (BC) is the most frequently occurring cancer of the urinary system, with non-muscle-invasive bladder cancer (NMIBC) accounting for 75-85% of all the bladder cancers. Patients with NMIBC have a good survival rate but are at high risk for tumor recurrence and disease progression. Intravesical instillation of antitumor agents is the standard treatment for NMIBC following transurethral resection of bladder tumors. Chemotherapeutic drugs are broadly employed for bladder cancer treatment, but have limited efficacy due to chemo-resistance and systemic toxicity. Additionally, the periodic voiding of bladder and low permeability of the bladder urothelium impair the retention of drugs, resulting in a weak antitumoral response. Chitosan is a non-toxic and biocompatible polymer which enables better penetration of specific drugs to the deeper cell layers of the bladder as a consequence of temporarily abolishing the barrier function of urothelium, thus offering multifaceted biomedical applications in urinary bladder epithelial. Nowadays, the rapid development of nanoparticles significantly improves the tumor therapy with enhanced drug transport. This review presents an overview on the state of chitosan-based nanoparticles in the field of intravesical bladder cancer treatment.

Keywords: bladder cancer; chitosan; intravesical drug delivery; nanoparticle.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Bladder wall anatomy.
Figure 2
Figure 2
Methods of preparation of chitosan nanoparticles.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021;71:7–33. doi: 10.3322/caac.21654. - DOI - PubMed
    1. Botteman M.F., Pashos C.L., Redaelli A., Laskin B., Hauser R. The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315–1330. doi: 10.1007/BF03262330. - DOI - PubMed
    1. Kaufman D.S. Challenges in the treatment of bladder cancer. Ann. Oncol. 2006;17:v106–v112. doi: 10.1093/annonc/mdj963. - DOI - PubMed
    1. Chang S.S., Boorjian S.A., Chou R., Clark P.E., Daneshmand S., Konety B.R., Pruthi R., Quale D.Z., Ritch C.R., Seigne J.D., et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J. Urol. 2016;196:1021–1029. doi: 10.1016/j.juro.2016.06.049. - DOI - PubMed
    1. Merrill L., Gonzalez E.J., Girard B.M., Vizzard M.A. Receptors, channels, and signalling in the urothelial sensory system in the bladder. Nat. Rev. Urol. 2016;13:193–204. doi: 10.1038/nrurol.2016.13. - DOI - PMC - PubMed